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M astocytosis or mast cell disease (MCD) repre-sents a group of clinical disorders that result .from the abnormal accumulation of mast cells in tissues, and conditions within the MCD spec-trum vary in regard to their clinical manifesta-
tions and extent of organ involvement [1-4] . 
In genera l, the diagnosis of MCD often can be established at the 
time of the physical examination because most, but not all, patients 
have relatively characteristic cutaneous lesions. The bedside m.a-
neuver of gen tl y stroking urticaria pigmentosum and telangiectasia 
macularis eruptiva perstans lesions usually results in a local wheal 
and flare reaction (Darier's sign) thereby substantiating the diagno-
sis [1-3]. Confirmation of cutaneous MCD is most readily aCCOITl-
plished by performing a biopsy of a characteristic lesion and 
demonstrating increased numbers of mast cells. Because methods 
for quantifying skin mast cells had yielded varying results, we 
combined the technique of morphometric point counting with the 
mast cell-specific fluorescein isothiocyanate-avidin stain to enu-
merate mast cells in normal skin and lesions of mastocytosis [5]. 
Using this approach, we observed that nodules, papules, aud 
telangiectatic macules of MCD had approximately a 150-, 40-, and 
9-fold increase in mast cell content, respectively, when compared 
to normal skin . Mo rphometric analysis of non-Iesional skin biopsies 
from these same patients and from lesional skin of patients with 
disorders that n"tight be confused with MCD such as urticaria, 
essential telangiectasis, and chronic eczema did not demonstrate 
significant increases in mast cells above controls. Taken together, 
these observations demonstrate that the diagnosis of MCD in the 
ski.n can be made on physical examination and confirmed by simple 
histologic techniques. 
But what are the criteria for the diagnosis of systemic MCD? 
Systemic MCD is defined as an increase in the number of mast cells 
in organs other than the skin. C linically there are some signs that 
may be helpful in establishing the diagnosis of systemic disease. 
Fifty percent or more of systemic MCD patients have hepatomeg-
aly, splenomegaly, andlor lymphadenopathy on physical examina-
tion [1, 6,7]. In addition, a number of these patients have bOl'le 
involvement that often can be visualized on skeletal x-rays o r 
radionucleotide bone scans [8,9]. More direct approaches also have 
been used to diagnose this systemic disorder. Increased numbers of 
mast cells have been reported in biopsies of liver andlor bOl~e 
marrow from some mastocytosis patients; however, because 9f the 
invasiveness of these procedures and their associated morbidities, 
attempts have been made to correlate levels of circulating mast cell 
mediators with the extent of MCD [1,4,6,10-13] . 
Mast cells arc known to produce pharmacologically potent 
molecules including histamine and prostaglandin D2 (PGD2), and 
the local and systemic release of these mediators contributes 
significantly to the spectrum of clinical signs and symptoms 0 b-
served in MCD patients [1,3,4]. Elevations in urin e and plasma 
histaminc Icvels have been documcnted in some systemic MCD 
patients during or immediately following symptomatic episodes 
[1,3] . However, random urinary histamine determinations have not 
proved useful in the diagnosis of systemic MCD, because ollly 
1-3% of this amine appears unmetabolized in the urine [10,11]. In 
contrast, the .major urinary histamine metabolites, NT -methyl-
histamine alid I-methyl-4-imidazoleacetic acid (MelmAA), are 
increased in patients with MCn and often are elevatcd in asymp-
tomatic patients with systemic involvement [10,11]. Granerus ct al 
have reported a direct correlation between urinary MelmAA levels 
and the extent of mast cell infiltration in the skin and other organs 
[10] . They noted the highest urinary excretion of MelmAA in 
patients with the most extensive disease. Elevated plasma levels of 
mast cell-derived tryptase also have been reported in some MCD 
patients; however, increased ci~cu l atil1g levels of this mediator have 
been identified in patients without MCD who experienced 311a-
phylaxis [1 2]. Increased urinary excretion of the major metabolite 
of PGD 2 (9-alpha,ll-beta-dihydroxy-15-oxo-2,3,18,19-tetranor-
prost-S-ene-l,20-dioicacid, ~)GD-M), also has been detected in 
patients with MCD. Initially, elevated levels of PGD-M were 
identified in a subgroup of MCD patients who experienced re-
peated episodes of flushing, hypotension, and syncope [13]. Inter-
estingly, many of these patients lacked persistent cutaneous lesions. 
This same investigative group has pursued PGD-M as a possible 
diagnostic tool for MCD, and in tlus month'sjoumal (p. 937), these 
authors have compared urinary levels of PGD-M to NT -mechylhis-
tamine as indicators of mastocytosis. In tlus report, 17 MCD were 
studied, all of which had persis'tent cutaneous lesions, and 11 of 15 
had increased numbers of bone-marrow mast cells. Twenty-four-
ho ur urine sa mple collections showed elevated levels ofPGD-M in 
16 of 17 patients whereas increased NT-metbylhistamine concen-
trations were found in only 12. In most patients, the magnitude of 
increases above nomlal values was greater for PGD-M than N T_ 
methyllustamine, thus leading the authors to conclude that the 
measurement of urinary PGD-M is a more sensitive test for MCD 
than N T -methyl-Iustamine. 
Although the measurement of urinary histamine metabolites and 
PGD-M levels have some merit in the evaluation of pa.tients with 
MCD, it is also important to recognize its limitations. For example, 
levels of urinary histamine and its metabolites can be affected by the 
dictal), intake of histamine or histidine [10,11,14]. In addition, 
diseases such as polycythemia vera and chrOluc myelocytic leuke-
mia have becn associated wi til persistent increases in urinary 
histamine metabolites [11]. Although elevations in PGD-M have 
been demonstrated in patients w ith MCD, they also have been 
documented in the serum and urine of normal volunteers after the 
ingestion of niacin [15]. In addition, increased levels of PGD-M 
havc been detected in a patient without MCD who experienced 
urticaria and bronchospasm, indicating that degranulation of nor-
mal numbers of mast cells in certain cLinical situations is capable of 
causing elevated levels of this metabolite [15] . Even the dircct 
enumeration of mast cells in the skin or bonc marrow is not 
absolutely specific for MCD. Increascd cutaneous mast cells have 
been reported in neurofibromas as well as several other ski.n 
tumors, and expanded bone-marrow mast cell populations have 
been associated with preleukemic, leukemic, and Iymphoprolifera-
tive disorders [16,17]. 
What can be surmised from this information? First, it is important 
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to emphasize that MCD is a spectrum with diverse clinical symp-
toms and signs; thus, it is likely that no single test would be 
absolutely diagnostic for this disease. Currently, the demonstration 
of increased mast cells in characteristic skin lesions comes the 
closes t to a "gold standard" test for MCD. Second, the detection of 
increased mast cells in other tissues or the finding of elevated levels 
of mast cell mediators in the peripheral ci rculation or urine must 
always be interpreted in the context of the clinical situation. In 
certain patients suspected of having systemic IViCD, but who lack 
typica l signs of the disorder, one or more of these tests may be 
useful. In reference to the measurement of PGD-M, the present 
study suggests that this test is a sensitive indicator of mast cell 
degranulation. W h at is not certain, how~ver, is whether it discrim-
inates patients with MCD from those experiencing other forms of 
mast celJ mediator release such as urticaria, asthma, and an aphy-
laxis. Additional studies comparing PGD-M levels in these two 
patient groups may be worthwhile, especiall y if significant differ-
ences can be demonstrated. 
Recently, there have been some advances in understanding mast 
cell development and maturation. T he cytokine stem cell factor 
(SCF) has been recognized for its importance in the growth of 
normal mast cells [1 8]. Increased expression of the soluble form of 
SCF has been reported in the skin ofMCD patients, thus suggesting 
that the overproduction of this cytokine may play a role in tlus 
disorder [19]. Future studies examining SCF and the regulation of 
its synthesis ll1ay prove important in understahding the pathogen-
esis of MCD and may lead to the development of new and 
innovative treatments for this disorder. 
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